Retroviruses Rapid Tests & Point of Care (POC) - Medical Devices Pipeline Assessment, 2017

Summary

GlobalData's Medical Devices sector report, Retroviruses Rapid Tests & Point of Care (POC) - Medical Devices Pipeline Assessment, 2017” provides an overview of Retroviruses Rapid Tests & Point of Care (POC) currently in pipeline stage.

The report provides comprehensive information on the pipeline products with comparative analysis of the products at various stages of development. The report reviews major players involved in the pipeline product development. It also provides information about clinical trials in progress, which includes trial phase, trial status, trial start and end dates, and, the number of trials for the key Retroviruses Rapid Tests & Point of Care (POC) pipeline products.

This report is prepared using data sourced from in-house databases, secondary and primary research by GlobalData's team of industry experts.

*Note: Certain sections in the report may be removed or altered based on the availability and relevance of data in relation to the equipment type.

Scope

- Extensive coverage of the Retroviruses Rapid Tests & Point of Care (POC) under development
- The report reviews details of major pipeline products which includes, product description, licensing and collaboration details and other developmental activities
- The report reviews the major players involved in the development of Retroviruses Rapid Tests & Point of Care
(POC) and list all their pipeline projects
- The coverage of pipeline products based on various stages of development ranging from Early Development to Approved / Issued stage
- The report provides key clinical trial data of ongoing trials specific to pipeline products
- Recent developments in the segment / industry

Reasons to buy

The report enables you to -
- Formulate significant competitor information, analysis, and insights to improve R&D strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Identify and understand important and diverse types of Retroviruses Rapid Tests & Point of Care (POC) under development
- Develop market-entry and market expansion strategies
- Plan mergers and acquisitions effectively by identifying major players with the most promising pipeline
- In-depth analysis of the products current stage of development, territory and estimated launch date

Table Of Content

Notes:

1
1.2
1.1 List of Tables 5
1.2 List of Figures 7
2 Introduction 8
2.1 Retroviruses Rapid Tests & Point of Care (POC) Overview 8
3 Products under Development 9
3.1 Retroviruses Rapid Tests & Point of Care (POC) - Pipeline Products by Stage of Development 9
3.2 Retroviruses Rapid Tests & Point of Care (POC) - Pipeline Products by Territory 10
3.3 Retroviruses Rapid Tests & Point of Care (POC) - Pipeline Products by Regulatory Path 11
3.4 Retroviruses Rapid Tests & Point of Care (POC) - Pipeline Products by Estimated Approval Date 12
4 Retroviruses Rapid Tests & Point of Care (POC) - Pipeline Products under Development by Companies 13
4.1 Retroviruses Rapid Tests & Point of Care (POC) Companies - Pipeline Products by Stage of Development 13
4.2 Retroviruses Rapid Tests & Point of Care (POC) - Pipeline Products by Stage of Development 15

5 Retroviruses Rapid Tests & Point of Care (POC) Companies and Product Overview 17

5.1 Akers Biosciences Inc Company Overview 17
5.1.1 Akers Biosciences Inc Pipeline Products & Ongoing Clinical Trials Overview 17

5.2 Aldatu Biosciences, Inc. Company Overview 19
5.2.1 Aldatu Biosciences, Inc. Pipeline Products & Ongoing Clinical Trials Overview 19

5.3 Atomo Diagnostics Pty Limited Company Overview 20
5.3.1 Atomo Diagnostics Pty Limited Pipeline Products & Ongoing Clinical Trials Overview 20

5.4 BBB Technologies Inc Company Overview 21
5.4.1 BBB Technologies Inc Pipeline Products & Ongoing Clinical Trials Overview 21

5.5 Bio-Alternative Medical Devices Ltd Company Overview 22
5.5.1 Bio-Alternative Medical Devices Ltd Pipeline Products & Ongoing Clinical Trials Overview 22

5.6 Biocartis SA Company Overview 23
5.6.1 Biocartis SA Pipeline Products & Ongoing Clinical Trials Overview 23

5.7 Biosynex SA Company Overview 24
5.7.1 Biosynex SA Pipeline Products & Ongoing Clinical Trials Overview 24

5.8 Calypte Biomedical Corporation Company Overview 25
5.8.1 Calypte Biomedical Corporation Pipeline Products & Ongoing Clinical Trials Overview 25

5.9 Centre International de Reference Chantal Biya Company Overview 27
5.9.1 Centre International de Reference Chantal Biya Pipeline Products & Ongoing Clinical Trials Overview 27

5.10 Cepheid Company Overview 28
5.10.1 Cepheid Pipeline Products & Ongoing Clinical Trials Overview 28

5.11 Chembio Diagnostic Systems Inc Company Overview 31
5.11.1 Chembio Diagnostic Systems Inc Pipeline Products & Ongoing Clinical Trials Overview 31

5.12 Daktari Diagnostics, Inc. Company Overview 34
5.12.1 Daktari Diagnostics, Inc. Pipeline Products & Ongoing Clinical Trials Overview 34

5.13 Diagnostics For All Company Overview 36
5.13.1 Diagnostics For All Pipeline Products & Ongoing Clinical Trials Overview 36

5.14 Diagnostics for the Real World (Europe) Ltd. Company Overview 37
5.14.1 Diagnostics for the Real World (Europe) Ltd. Pipeline Products & Ongoing Clinical Trials Overview 37

5.15 Epinex Diagnostics Inc Company Overview 38
5.15.1 Epinex Diagnostics Inc Pipeline Products & Ongoing Clinical Trials Overview 38

5.16 ERBA Molecular Ltd Company Overview 39
5.16.1 ERBA Molecular Ltd Pipeline Products & Ongoing Clinical Trials Overview 39
<table>
<thead>
<tr>
<th>5.17</th>
<th>GAIA Medical Institute LLC Company Overview 40</th>
</tr>
</thead>
<tbody>
<tr>
<td>5.17.1</td>
<td>GAIA Medical Institute LLC Pipeline Products &amp; Ongoing Clinical Trials Overview 40</td>
</tr>
<tr>
<td>5.18</td>
<td>genedrive plc Company Overview 41</td>
</tr>
<tr>
<td>5.18.1</td>
<td>genedrive plc Pipeline Products &amp; Ongoing Clinical Trials Overview 41</td>
</tr>
<tr>
<td>5.19</td>
<td>Group K Diagnostics Company Overview 42</td>
</tr>
<tr>
<td>5.19.1</td>
<td>Group K Diagnostics Pipeline Products &amp; Ongoing Clinical Trials Overview 42</td>
</tr>
<tr>
<td>5.20</td>
<td>HeatFlow Technologies Inc Company Overview 43</td>
</tr>
<tr>
<td>5.20.1</td>
<td>HeatFlow Technologies Inc Pipeline Products &amp; Ongoing Clinical Trials Overview 43</td>
</tr>
<tr>
<td>5.21</td>
<td>Jinvator Bio Med GmbH Company Overview 44</td>
</tr>
<tr>
<td>5.21.1</td>
<td>Jinvator Bio Med GmbH Pipeline Products &amp; Ongoing Clinical Trials Overview 44</td>
</tr>
<tr>
<td>5.22</td>
<td>John Hopkins University Company Overview 45</td>
</tr>
<tr>
<td>5.22.1</td>
<td>John Hopkins University Pipeline Products &amp; Ongoing Clinical Trials Overview 45</td>
</tr>
<tr>
<td>5.23</td>
<td>Labsystems Diagnostics Oy Company Overview 46</td>
</tr>
<tr>
<td>5.23.1</td>
<td>Labsystems Diagnostics Oy Pipeline Products &amp; Ongoing Clinical Trials Overview 46</td>
</tr>
<tr>
<td>5.24</td>
<td>Micronics Inc Company Overview 47</td>
</tr>
<tr>
<td>5.24.1</td>
<td>Micronics Inc Pipeline Products &amp; Ongoing Clinical Trials Overview 47</td>
</tr>
<tr>
<td>5.25</td>
<td>Molbio Diagnostics Pvt. Ltd. Company Overview 49</td>
</tr>
<tr>
<td>5.25.1</td>
<td>Molbio Diagnostics Pvt. Ltd. Pipeline Products &amp; Ongoing Clinical Trials Overview 49</td>
</tr>
<tr>
<td>5.26</td>
<td>Northwestern Global Health Foundation Company Overview 50</td>
</tr>
<tr>
<td>5.26.1</td>
<td>Northwestern Global Health Foundation Pipeline Products &amp; Ongoing Clinical Trials Overview 50</td>
</tr>
<tr>
<td>5.27</td>
<td>NOWDiagnostics Company Overview 51</td>
</tr>
<tr>
<td>5.27.1</td>
<td>NOWDiagnostics Pipeline Products &amp; Ongoing Clinical Trials Overview 51</td>
</tr>
<tr>
<td>5.28</td>
<td>Omega Diagnostics Group Plc Company Overview 52</td>
</tr>
<tr>
<td>5.28.1</td>
<td>Omega Diagnostics Group Plc Pipeline Products &amp; Ongoing Clinical Trials Overview 52</td>
</tr>
<tr>
<td>5.29</td>
<td>OPKO Health Inc Company Overview 53</td>
</tr>
<tr>
<td>5.29.1</td>
<td>OPKO Health Inc Pipeline Products &amp; Ongoing Clinical Trials Overview 53</td>
</tr>
<tr>
<td>5.30</td>
<td>OraSure Technologies Inc Company Overview 54</td>
</tr>
<tr>
<td>5.30.1</td>
<td>OraSure Technologies Inc Pipeline Products &amp; Ongoing Clinical Trials Overview 54</td>
</tr>
<tr>
<td>5.31</td>
<td>Osel Inc Company Overview 55</td>
</tr>
<tr>
<td>5.31.1</td>
<td>Osel Inc Pipeline Products &amp; Ongoing Clinical Trials Overview 55</td>
</tr>
<tr>
<td>5.32</td>
<td>QuantuMDx Group Ltd Company Overview 56</td>
</tr>
<tr>
<td>5.32.1</td>
<td>QuantuMDx Group Ltd Pipeline Products &amp; Ongoing Clinical Trials Overview 56</td>
</tr>
<tr>
<td>5.33</td>
<td>Quidel Corp Company Overview 57</td>
</tr>
<tr>
<td>5.33.1</td>
<td>Quidel Corp Pipeline Products &amp; Ongoing Clinical Trials Overview 57</td>
</tr>
</tbody>
</table>
5.34 Radisens Diagnostics Ltd Company Overview 60
5.34.1 Radisens Diagnostics Ltd Pipeline Products & Ongoing Clinical Trials Overview 60
5.35 Rheonix Inc Company Overview 61
5.35.1 Rheonix Inc Pipeline Products & Ongoing Clinical Trials Overview 61
5.36 Roche Diagnostics International Ltd Company Overview 62
5.36.1 Roche Diagnostics International Ltd Pipeline Products & Ongoing Clinical Trials Overview 62
5.37 Sedia Biosciences Corp Company Overview 63
5.37.1 Sedia Biosciences Corp Pipeline Products & Ongoing Clinical Trials Overview 63
5.38 Trinity Biotech Plc Company Overview 65
5.38.1 Trinity Biotech Plc Pipeline Products & Ongoing Clinical Trials Overview 65
5.39 Wave 80 Biosciences Inc Company Overview 66
5.39.1 Wave 80 Biosciences Inc Pipeline Products & Ongoing Clinical Trials Overview 66
6 Retroviruses Rapid Tests & Point of Care (POC)- Recent Developments 68
6.1 Jul 26, 2017: Quidel Reports Second Quarter 2017 Financial Results 68
6.3 Jul 21, 2017: OraSure Technologies Receives World Health Organization Prequalification of OraQuick HIV Self-Test 70
6.4 Jul 20, 2017: Trinity Biotech Announces Results for Q2, 2017 71
6.5 Jul 18, 2017: Johnson & Johnson Reports 2017 Second-Quarter Results 72
6.6 Jun 27, 2017: OraSure Technologies to Drive Accelerated Adoption of OraQuick HIV Self-Test 74
6.7 May 17, 2017: VANC Pharmaceuticals Announces Canadian Distribution Agreement for INSTI HIV-1/HIV-2 Antibody Test 75
6.8 May 16, 2017: NOWDiagnostics CEO Kevin Clark to Address Technology Conference 76
6.9 May 03, 2017: Chembio Secures $5.8 Million Bio-Manguinhos Order to Supply Components for Production of DPP HIV 1/2 Assay in Brazil 76
6.10 Apr 27, 2017: Trinity Biotech Announces Results for Q1, 2017 77
6.11 Apr 24, 2017: Quidel Reports First Quarter 2017 Financial Results 78
6.12 Apr 19, 2017: Johnson & Johnson reports Q1 2017 results 79
6.13 Apr 18, 2017: Johnson & Johnson Reports 2017 First-Quarter Results 81
6.14 Mar 14, 2017: Trinity Biotech announces Quarter 4 and Fiscal Year 2016 Financial Results 83
6.15 Mar 01, 2017: OraSure Receives Global Fund Classification to Enable HIV Self-Test Procurement 86
6.17 Feb 08, 2017: Quidel Reports Fourth Quarter and Full Year 2016 Financial Results 87
6.18 Jan 24, 2017: Johnson & Johnson Reports 2016 Fourth-Quarter Results 88
6.19 Jan 23, 2017: Quidel Announces Modification of Revenue Reporting Categories 90
6.20 Jan 09, 2017: Johnson & Johnson Medical Devices Companies Launch CareAdvantage, a Suite of Holistic, Insights-Driven Capabilities to Help U.S. Health Systems Navigate Value-Based Care 91
6.21 Jan 06, 2017: Quidel Announces Preliminary Revenue for Fourth Quarter 2016 92
6.22 Dec 01, 2016: Daktari Awarded $1.3 Million NIH SBIR Grant for HIV Point-of-Care Diagnostic 92
6.23 Oct 26, 2016: Quidel Reports Third Quarter 2016 Financial Results 93
6.25 Oct 25, 2016: Researchers Use CRISPR to Accelerate Search for HIV Cure 97
6.26 Oct 18, 2016: Johnson & Johnson Reports 2016 Third-Quarter Results 98
6.27 Sep 08, 2016: Cepheid Targets Development of a Point of Care HIV Viral Load Test From a Few Drops of Blood 100

7 Appendix 102
7.1 Methodology 102
7.2 About GlobalData 105
7.3 Contact Us 105
7.4 Disclaimer 105

1.1 List of Tables
Table 1: Retroviruses Rapid Tests & Point of Care (POC) - Pipeline Products by Stage of Development 9
Table 2: Retroviruses Rapid Tests & Point of Care (POC) - Pipeline Products by Territory 10
Table 3: Retroviruses Rapid Tests & Point of Care (POC) - Pipeline Products by Regulatory Path 11
Table 4: Retroviruses Rapid Tests & Point of Care (POC) - Pipeline Products by Estimated Approval Date 12
Table 5: Retroviruses Rapid Tests & Point of Care (POC) Companies - Pipeline Products by Stage of Development 13
Table 6: Retroviruses Rapid Tests & Point of Care (POC) - Pipeline Products by Stage of Development 15
Table 7: Akers Biosciences Inc Pipeline Products & Ongoing Clinical Trials Overview 17
Table 8: PIFA HIV 1+2 Rapid Assay - Product Status 17
Table 9: PIFA HIV 1+2 Rapid Assay - Product Description 18
Table 10: Aldatu Biosciences, Inc. Pipeline Products & Ongoing Clinical Trials Overview 19
Table 11: PANDAA HIV6 - Product Status 19
Table 12: PANDAA HIV6 - Product Description 19
Table 13: Atomo Diagnostics Pty Limited Pipeline Products & Ongoing Clinical Trials Overview 20
Table 14: AtomoRapid HIV - Product Status 20
Table 15: AtomoRapid HIV - Product Description 20
Table 16: BBB Technologies Inc Pipeline Products & Ongoing Clinical Trials Overview 21
Table 17: Mobile RDT Reader - HIV1/2 Test - Product Status 21
Table 18: Mobile RDT Reader - HIV1/2 Test - Product Description 21
Table 19: Bio-Alternative Medical Devices Ltd Pipeline Products & Ongoing Clinical Trials Overview 22
Table 20: Digital Strip Reader - HIV - Product Status 22
Table 21: Digital Strip Reader - HIV - Product Description 22
Table 22: Biocartis SA Pipeline Products & Ongoing Clinical Trials Overview 23
Table 23: Idylla Viral Load Assay - HIV - Product Status 23
Table 24: Idylla Viral Load Assay - HIV - Product Description 23
Table 25: Biosynex SA Pipeline Products & Ongoing Clinical Trials Overview 24
Table 26: Exacto HIV Screening Test - Product Status 24
Table 27: Exacto HIV Screening Test - Product Description 24
Table 28: Calypte Biomedical Corporation Pipeline Products & Ongoing Clinical Trials Overview 25
Table 29: Aware 2 HIV-1/2 - Product Status 25
Table 30: Aware 2 HIV-1/2 - Product Description 25
Table 31: Aware HIV-1/2 OMT - Product Status 26
Table 32: Aware HIV-1/2 OMT - Product Description 26
Table 33: Centre International de Reference Chantal Biya Pipeline Products & Ongoing Clinical Trials Overview 27
Table 34: Point-Of-Care Diagnostic Test - HIV-1 - Product Status 27
Table 35: Point-Of-Care Diagnostic Test - HIV-1 - Product Description 27
Table 36: Cepheid Pipeline Products & Ongoing Clinical Trials Overview 28
Table 37: GeneXpert Omni - Xpert HIV-1 Qualitative - Product Status 28
Table 38: GeneXpert Omni - Xpert HIV-1 Qualitative - Product Description 28
Table 39: GeneXpert Omni - Xpert HIV-1 Viral Load - Product Status 29
Table 40: GeneXpert Omni - Xpert HIV-1 Viral Load - Product Description 29
Table 41: Xpert Finger Stick HIV-1 Viral Load Assay - Product Status 29
Table 42: Xpert Finger Stick HIV-1 Viral Load Assay - Product Description 30
Table 43: Chembio Diagnostic Systems Inc Pipeline Products & Ongoing Clinical Trials Overview 31
Table 44: DPP HIV Ag-Ab Assay - Product Status 31
Table 45: DPP HIV Ag-Ab Assay - Product Description 31
Table 46: Next Generation DPP HIV Oral Fluid Assay - Product Status 32
Table 47: Next Generation DPP HIV Oral Fluid Assay - Product Description 32
<table>
<thead>
<tr>
<th>Table</th>
<th>Description</th>
</tr>
</thead>
<tbody>
<tr>
<td>Table 48</td>
<td>Sure Check HIV OTC Assay - Product Status 32</td>
</tr>
<tr>
<td>Table 49</td>
<td>Sure Check HIV OTC Assay - Product Description 33</td>
</tr>
<tr>
<td>Table 50</td>
<td>Dakteri Diagnostics, Inc. Pipeline Products &amp; Ongoing Clinical Trials Overview 34</td>
</tr>
<tr>
<td>Table 51</td>
<td>Aspect - HIV Viral Load Test - Product Status 34</td>
</tr>
<tr>
<td>Table 52</td>
<td>Aspect - HIV Viral Load Test - Product Description 34</td>
</tr>
<tr>
<td>Table 53</td>
<td>HIV Viral Load Test - Product Status 35</td>
</tr>
<tr>
<td>Table 54</td>
<td>HIV Viral Load Test - Product Description 35</td>
</tr>
<tr>
<td>Table 55</td>
<td>Diagnostics For All Pipeline Products &amp; Ongoing Clinical Trials Overview 36</td>
</tr>
<tr>
<td>Table 56</td>
<td>Paper-Based Microfluidic Device - HIV - Product Status 36</td>
</tr>
<tr>
<td>Table 57</td>
<td>Paper-Based Microfluidic Device - HIV - Product Description 36</td>
</tr>
<tr>
<td>Table 58</td>
<td>Diagnostics for the Real World (Europe) Ltd. Pipeline Products &amp; Ongoing Clinical Trials Overview 37</td>
</tr>
<tr>
<td>Table 59</td>
<td>SAMBA - HIV-1 Viral Load Assay - Product Status 37</td>
</tr>
<tr>
<td>Table 60</td>
<td>SAMBA - HIV-1 Viral Load Assay - Product Description 37</td>
</tr>
<tr>
<td>Table 61</td>
<td>Epinex Diagnostics Inc Pipeline Products &amp; Ongoing Clinical Trials Overview 38</td>
</tr>
<tr>
<td>Table 62</td>
<td>Epinex G1A - Neo-natal HIV Test - Product Status 38</td>
</tr>
<tr>
<td>Table 63</td>
<td>Epinex G1A - Neo-natal HIV Test - Product Description 38</td>
</tr>
<tr>
<td>Table 64</td>
<td>ERBA Molecular Ltd Pipeline Products &amp; Ongoing Clinical Trials Overview 39</td>
</tr>
<tr>
<td>Table 65</td>
<td>Next Generation HIV Viral Load Monitoring Test - Product Status 39</td>
</tr>
<tr>
<td>Table 66</td>
<td>Next Generation HIV Viral Load Monitoring Test - Product Description 39</td>
</tr>
<tr>
<td>Table 67</td>
<td>GAIA Medical Institute LLC Pipeline Products &amp; Ongoing Clinical Trials Overview 40</td>
</tr>
<tr>
<td>Table 68</td>
<td>Point-Of-Care Diagnostic Test - HIV - Product Status 40</td>
</tr>
<tr>
<td>Table 69</td>
<td>Point-Of-Care Diagnostic Test - HIV - Product Description 40</td>
</tr>
<tr>
<td>Table 70</td>
<td>genedrive plc Pipeline Products &amp; Ongoing Clinical Trials Overview 41</td>
</tr>
<tr>
<td>Table 71</td>
<td>Genedrive - HIV Assay - Product Status 41</td>
</tr>
<tr>
<td>Table 72</td>
<td>Genedrive - HIV Assay - Product Description 41</td>
</tr>
<tr>
<td>Table 73</td>
<td>Group K Diagnostics Pipeline Products &amp; Ongoing Clinical Trials Overview 42</td>
</tr>
<tr>
<td>Table 74</td>
<td>Multidiagnostic - HIV Load Test - Product Status 42</td>
</tr>
<tr>
<td>Table 75</td>
<td>Multidiagnostic - HIV Load Test - Product Description 42</td>
</tr>
<tr>
<td>Table 76</td>
<td>HeatFlow Technologies Inc Pipeline Products &amp; Ongoing Clinical Trials Overview 43</td>
</tr>
<tr>
<td>Table 77</td>
<td>HF-PCR Point Of Care HIV Viral Load Assay - Product Status 43</td>
</tr>
<tr>
<td>Table 78</td>
<td>HF-PCR Point Of Care HIV Viral Load Assay - Product Description 43</td>
</tr>
<tr>
<td>Table 79</td>
<td>Jinvator Bio Med GmbH Pipeline Products &amp; Ongoing Clinical Trials Overview 44</td>
</tr>
<tr>
<td>Table 80</td>
<td>nanoGold Test - Product Status 44</td>
</tr>
<tr>
<td>Table 81</td>
<td>nanoGold Test - Product Description 44</td>
</tr>
</tbody>
</table>
Table 82: John Hopkins University Pipeline Products & Ongoing Clinical Trials Overview 45
Table 83: Point-Of-Care Test - Pediatric HIV - Product Status 45
Table 84: Point-Of-Care Test - Pediatric HIV - Product Description 45
Table 85: Labsystems Diagnostics Oy Pipeline Products & Ongoing Clinical Trials Overview 46
Table 86: Biocard HIV (1+2) Test - Product Status 46
Table 87: Biocard HIV (1+2) Test - Product Description 46
Table 88: Micronics Inc Pipeline Products & Ongoing Clinical Trials Overview 47
Table 89: MTCT - HIV Assay - Product Status 47
Table 90: MTCT - HIV Assay - Product Description 47
Table 91: PanNAT - HIV Assay - Product Status 48
Table 92: PanNAT - HIV Assay - Product Description 48
Table 93: Molbio Diagnostics Pvt. Ltd. Pipeline Products & Ongoing Clinical Trials Overview 49
Table 94: Truenat HIV Viral Load Assay - Product Status 49
Table 95: Truenat HIV Viral Load Assay - Product Description 49
Table 96: Northwestern Global Health Foundation Pipeline Products & Ongoing Clinical Trials Overview 50
Table 97: LYNX HIV p24 Antigen Test - Product Status 50
Table 98: LYNX HIV p24 Antigen Test - Product Description 50
Table 99: NOWDiagnostics Pipeline Products & Ongoing Clinical Trials Overview 51
Table 100: ADEXUSDx HIV Test - Product Status 51
Table 101: ADEXUSDx HIV Test - Product Description 51
Table 102: Omega Diagnostics Group Plc Pipeline Products & Ongoing Clinical Trials Overview 52
Table 103: VISITECT CD4 Test - Product Status 52
Table 104: VISITECT CD4 Test - Product Description 52
Table 105: OPKO Health Inc Pipeline Products & Ongoing Clinical Trials Overview 53
Table 106: Diagnostic Assay - HIV - Product Status 53
Table 107: Diagnostic Assay - HIV - Product Description 53
Table 108: OraSure Technologies Inc Pipeline Products & Ongoing Clinical Trials Overview 54
Table 109: Next Generation OraQuick Rapid HIV Test - Product Status 54
Table 110: Next Generation OraQuick Rapid HIV Test - Product Description 54
Table 111: Osel Inc Pipeline Products & Ongoing Clinical Trials Overview 55
Table 112: Point-Of-Care Diagnostic Test - HIV-1 Infection - Product Status 55
Table 113: Point-Of-Care Diagnostic Test - HIV-1 Infection - Product Description 55
Table 114: QuantuMDx Group Ltd Pipeline Products & Ongoing Clinical Trials Overview 56
Table 115: Q-POC - HIV Assay - Product Status 56
1.2 List of Figures

Figure 1: Retroviruses Rapid Tests & Point of Care (POC) - Pipeline Products by Stage of Development 9